Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) were down 2.1% during mid-day trading on Tuesday. The stock traded as low as $1.37 and last traded at $1.37. 44,085 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.40.
Virios Therapeutics Trading Down 2.3%
The company has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $1.73. The firm has a market cap of $24.46 million, a PE ratio of -4.70 and a beta of 1.58.
About Virios Therapeutics
Virios Therapeutics, Inc (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing treatments for diseases associated with abnormal immune responses to latent viral infections. The company’s research has primarily centered on fibromyalgia, a chronic condition characterized by widespread pain and other symptoms.
Virios Therapeutics’ lead product candidate is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory medicine.
See Also
- Five stocks we like better than Virios Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
